Ionis Pharmaceuticals Inc (IONS) stock
IONSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/303% below fair value
$27.39+0.43 (+1.59%)
Close on Nov 18, 2026Market cap $4.55BP/E –Yield –
Ionis Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Ionis Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $874.09M, down 7.4% year over year. For fiscal 2025 it was $943.71M, up 33.8% from the year before. Over ten years it grew 12.8% a year on average. The highest annual figure on record is $1.12B in fiscal 2019.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $943.71M | +33.8% |
| FY2024 | Dec 31, 2024 | $705.14M | -10.5% |
| FY2023 | Dec 31, 2023 | $787.65M | +34.1% |
| FY2022 | Dec 31, 2022 | $587.37M | -27.5% |
| FY2021 | Dec 31, 2021 | $810.46M | +11.1% |
| FY2020 | Dec 31, 2020 | $729.26M | -35.0% |
| FY2019 | Dec 31, 2019 | $1.12B | +87.2% |
| FY2018 | Dec 31, 2018 | $599.67M | +16.6% |
| FY2017 | Dec 31, 2017 | $514.18M | +37.9% |
| FY2016 | Dec 31, 2016 | $372.78M | +31.4% |
| FY2015 | Dec 31, 2015 | $283.70M | +32.5% |
| FY2014 | Dec 31, 2014 | $214.16M | +45.4% |
| FY2013 | Dec 31, 2013 | $147.29M | +44.3% |
| FY2012 | Dec 31, 2012 | $102.05M | +3.0% |
| FY2011 | Dec 31, 2011 | $99.09M | -8.7% |
| FY2010 | Dec 31, 2010 | $108.47M | -10.8% |
| FY2009 | Dec 31, 2009 | $121.60M | +13.4% |
| FY2008 | Dec 31, 2008 | $107.19M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $267.95M | -40.7% |
| Q1 FY2026 | Mar 31, 2026 | $246.09M | +87.0% |
| Q4 FY2025 | Dec 31, 2025 | $203.33M | -10.3% |
| Q3 FY2025 | Sep 30, 2025 | $156.72M | +17.1% |
| Q2 FY2025 | Jun 30, 2025 | $452.05M | +100.7% |
| Q1 FY2025 | Mar 31, 2025 | $131.61M | +10.1% |
| Q4 FY2024 | Dec 31, 2024 | $226.58M | -30.2% |
| Q3 FY2024 | Sep 30, 2024 | $133.81M | -7.2% |
| Q2 FY2024 | Jun 30, 2024 | $225.25M | +19.6% |
| Q1 FY2024 | Mar 31, 2024 | $119.50M | -8.4% |
| Q4 FY2023 | Dec 31, 2023 | $324.51M | +113.6% |
| Q3 FY2023 | Sep 30, 2023 | $144.21M | -9.7% |
| Q2 FY2023 | Jun 30, 2023 | $188.41M | +40.8% |
| Q1 FY2023 | Mar 31, 2023 | $130.52M | -8.0% |
| Q4 FY2022 | Dec 31, 2022 | $151.89M | -65.5% |
| Q3 FY2022 | Sep 30, 2022 | $159.77M | +20.0% |
| Q2 FY2022 | Jun 30, 2022 | $133.79M | +6.4% |
| Q1 FY2022 | Mar 31, 2022 | $141.92M | +27.2% |
| Q4 FY2021 | Dec 31, 2021 | $440.01M | +51.6% |
| Q3 FY2021 | Sep 30, 2021 | $133.09M | -16.9% |
| Q2 FY2021 | Jun 30, 2021 | $125.75M | -13.6% |
| Q1 FY2021 | Mar 31, 2021 | $111.61M | -16.3% |
| Q4 FY2020 | Dec 31, 2020 | $290.28M | -41.2% |
| Q3 FY2020 | Sep 30, 2020 | $160.08M | -4.7% |
| Q2 FY2020 | Jun 30, 2020 | $145.54M | -11.2% |
| Q1 FY2020 | Mar 31, 2020 | $133.37M | -55.1% |
| Q4 FY2019 | Dec 31, 2019 | $493.68M | +157.0% |
| Q3 FY2019 | Sep 30, 2019 | $167.89M | +15.5% |
| Q2 FY2019 | Jun 30, 2019 | $163.81M | +39.1% |
| Q1 FY2019 | Mar 31, 2019 | $297.21M | +105.8% |
| Q4 FY2018 | Dec 31, 2018 | $192.11M | +14.5% |
| Q3 FY2018 | Sep 30, 2018 | $145.40M | +22.9% |
| Q2 FY2018 | Jun 30, 2018 | $117.75M | +4.9% |
| Q1 FY2018 | Mar 31, 2018 | $144.42M | +24.7% |
| Q4 FY2017 | Dec 31, 2017 | $167.79M | +4.6% |
| Q3 FY2017 | Sep 30, 2017 | $118.31M | +6.7% |
| Q2 FY2017 | Jun 30, 2017 | $112.27M | – |
| Q1 FY2017 | Mar 31, 2017 | $115.80M | – |
| Q4 FY2016 | Dec 31, 2016 | $160.35M | – |
| Q3 FY2016 | Sep 30, 2016 | $110.93M | – |
See a number that looks wrong?